nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.101	0.182	CbGbCtD
Bexarotene—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.101	0.182	CbGbCtD
Bexarotene—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0777	0.14	CbGbCtD
Bexarotene—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0767	0.138	CbGbCtD
Bexarotene—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0525	0.0945	CbGbCtD
Bexarotene—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0501	0.0902	CbGbCtD
Bexarotene—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0446	0.0804	CbGbCtD
Bexarotene—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0262	0.0472	CbGbCtD
Bexarotene—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0247	0.0445	CbGbCtD
Bexarotene—RXRB—Vitamin D Metabolism—GC—chronic obstructive pulmonary disease	0.0163	0.152	CbGpPWpGaD
Bexarotene—RXRA—Vitamin D Metabolism—GC—chronic obstructive pulmonary disease	0.00847	0.0792	CbGpPWpGaD
Bexarotene—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00343	0.0321	CbGpPWpGaD
Bexarotene—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00303	0.0284	CbGpPWpGaD
Bexarotene—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00248	0.0232	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—ADIPOQ—chronic obstructive pulmonary disease	0.00208	0.0194	CbGpPWpGaD
Bexarotene—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—CTGF—chronic obstructive pulmonary disease	0.00178	0.0166	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00172	0.016	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—ERBB3—chronic obstructive pulmonary disease	0.00166	0.0155	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00159	0.0149	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00156	0.0146	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB3—chronic obstructive pulmonary disease	0.00156	0.0146	CbGpPWpGaD
Bexarotene—RXRA—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.0013	0.0122	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—LEP—chronic obstructive pulmonary disease	0.00129	0.0121	CbGpPWpGaD
Bexarotene—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00126	0.0118	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00125	0.0117	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—chronic obstructive pulmonary disease	0.00114	0.0107	CbGpPWpGaD
Bexarotene—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00114	0.0106	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—chronic obstructive pulmonary disease	0.00107	0.01	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—chronic obstructive pulmonary disease	0.00107	0.00996	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—ADIPOQ—chronic obstructive pulmonary disease	0.00102	0.00957	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—chronic obstructive pulmonary disease	0.001	0.00937	CbGpPWpGaD
Bexarotene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000966	0.00902	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000918	0.00857	CbGpPWpGaD
Bexarotene—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000825	0.00771	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000823	0.00769	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000822	0.00768	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—ERBB3—chronic obstructive pulmonary disease	0.000814	0.00761	CbGpPWpGaD
Bexarotene—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000793	0.00741	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—ADIPOQ—chronic obstructive pulmonary disease	0.000763	0.00713	CbGpPWpGaD
Bexarotene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000749	0.007	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000744	0.00695	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—chronic obstructive pulmonary disease	0.000722	0.00675	CbGpPWpGaD
Bexarotene—RXRA—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.000682	0.00637	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—chronic obstructive pulmonary disease	0.000679	0.00634	CbGpPWpGaD
Bexarotene—RXRA—BMAL1:CLOCK,NPAS2 activates circadian gene expression—SERPINE1—chronic obstructive pulmonary disease	0.000668	0.00624	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000667	0.00623	CbGpPWpGaD
Bexarotene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00065	0.00608	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—LEP—chronic obstructive pulmonary disease	0.000636	0.00594	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—CTGF—chronic obstructive pulmonary disease	0.000613	0.00573	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000605	0.00565	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—chronic obstructive pulmonary disease	0.0006	0.00561	CbGpPWpGaD
Bexarotene—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000599	0.0056	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—TNF—chronic obstructive pulmonary disease	0.000597	0.00558	CbGpPWpGaD
Bexarotene—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000592	0.00553	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000586	0.00547	CbGpPWpGaD
Bexarotene—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000576	0.00539	CbGpPWpGaD
Bexarotene—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000567	0.0053	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—chronic obstructive pulmonary disease	0.00056	0.00523	CbGpPWpGaD
Bexarotene—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000544	0.00508	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00054	0.00505	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.00054	0.00504	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000539	0.00504	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000536	0.00501	CbGpPWpGaD
Bexarotene—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000523	0.00489	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—chronic obstructive pulmonary disease	0.000523	0.00488	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000508	0.00475	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—ADIPOQ—chronic obstructive pulmonary disease	0.000502	0.00469	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000499	0.00466	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000498	0.00465	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—SERPINE1—chronic obstructive pulmonary disease	0.000487	0.00455	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IL6—chronic obstructive pulmonary disease	0.000482	0.0045	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000475	0.00444	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—LEP—chronic obstructive pulmonary disease	0.000474	0.00443	CbGpPWpGaD
Bexarotene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000473	0.00441	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00047	0.00439	CbGpPWpGaD
Bexarotene—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000454	0.00424	CbGpPWpGaD
Bexarotene—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00043	0.00402	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—chronic obstructive pulmonary disease	0.000414	0.00386	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—CYP1A1—chronic obstructive pulmonary disease	0.00041	0.00384	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—chronic obstructive pulmonary disease	0.000402	0.00375	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.0004	0.00374	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000396	0.0037	CbGpPWpGaD
Bexarotene—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000395	0.00369	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000395	0.00369	CbGpPWpGaD
Bexarotene—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00038	0.00355	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000376	0.00351	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000376	0.00351	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000371	0.00346	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000356	0.00332	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000354	0.00105	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—chronic obstructive pulmonary disease	0.000354	0.00331	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000353	0.00105	CcSEcCtD
Bexarotene—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000352	0.00104	CcSEcCtD
Bexarotene—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000352	0.00104	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00035	0.00327	CbGpPWpGaD
Bexarotene—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00103	CcSEcCtD
Bexarotene—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00103	CcSEcCtD
Bexarotene—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00103	CcSEcCtD
Bexarotene—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000348	0.00103	CcSEcCtD
Bexarotene—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.00102	CcSEcCtD
Bexarotene—Infection—Formoterol—chronic obstructive pulmonary disease	0.000346	0.00102	CcSEcCtD
Bexarotene—RXRA—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000345	0.00323	CbGpPWpGaD
Bexarotene—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00102	CcSEcCtD
Bexarotene—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00102	CcSEcCtD
Bexarotene—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00102	CcSEcCtD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000343	0.0032	CbGpPWpGaD
Bexarotene—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000342	0.00101	CcSEcCtD
Bexarotene—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00101	CcSEcCtD
Bexarotene—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00101	CcSEcCtD
Bexarotene—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.001	CcSEcCtD
Bexarotene—Infection—Montelukast—chronic obstructive pulmonary disease	0.000339	0.001	CcSEcCtD
Bexarotene—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000339	0.001	CcSEcCtD
Bexarotene—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000339	0.001	CcSEcCtD
Bexarotene—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.001	CcSEcCtD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000338	0.00316	CbGpPWpGaD
Bexarotene—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000338	0.000999	CcSEcCtD
Bexarotene—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.000994	CcSEcCtD
Bexarotene—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000335	0.000991	CcSEcCtD
Bexarotene—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000334	0.000989	CcSEcCtD
Bexarotene—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000334	0.000989	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000334	0.00312	CbGpPWpGaD
Bexarotene—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000334	0.000987	CcSEcCtD
Bexarotene—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000332	0.000981	CcSEcCtD
Bexarotene—RXRA—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.00033	0.00308	CbGpPWpGaD
Bexarotene—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.000974	CcSEcCtD
Bexarotene—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000327	0.000968	CcSEcCtD
Bexarotene—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000326	0.000963	CcSEcCtD
Bexarotene—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000324	0.000959	CcSEcCtD
Bexarotene—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000324	0.000958	CcSEcCtD
Bexarotene—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.000955	CcSEcCtD
Bexarotene—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.000951	CcSEcCtD
Bexarotene—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.000946	CcSEcCtD
Bexarotene—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000318	0.000942	CcSEcCtD
Bexarotene—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000318	0.000942	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000318	0.00094	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000318	0.00094	CcSEcCtD
Bexarotene—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000315	0.000933	CcSEcCtD
Bexarotene—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000315	0.000933	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	0.000315	0.00294	CbGpPWpGaD
Bexarotene—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000314	0.000928	CcSEcCtD
Bexarotene—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000313	0.000927	CcSEcCtD
Bexarotene—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000312	0.000923	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—LEP—chronic obstructive pulmonary disease	0.000312	0.00291	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000311	0.00092	CcSEcCtD
Bexarotene—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000311	0.00092	CcSEcCtD
Bexarotene—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.00092	CcSEcCtD
Bexarotene—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00031	0.000917	CcSEcCtD
Bexarotene—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00031	0.000917	CcSEcCtD
Bexarotene—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000309	0.000914	CcSEcCtD
Bexarotene—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000911	CcSEcCtD
Bexarotene—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000307	0.000908	CcSEcCtD
Bexarotene—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000307	0.000908	CcSEcCtD
Bexarotene—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000307	0.000907	CcSEcCtD
Bexarotene—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000306	0.000904	CcSEcCtD
Bexarotene—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000304	0.000898	CcSEcCtD
Bexarotene—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000303	0.000896	CcSEcCtD
Bexarotene—RXRA—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000303	0.00283	CbGpPWpGaD
Bexarotene—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000302	0.000894	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000301	0.000891	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000301	0.000891	CcSEcCtD
Bexarotene—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000301	0.000889	CcSEcCtD
Bexarotene—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000301	0.000889	CcSEcCtD
Bexarotene—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000301	0.000889	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.000887	CcSEcCtD
Bexarotene—Pain—Formoterol—chronic obstructive pulmonary disease	0.000298	0.000882	CcSEcCtD
Bexarotene—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000298	0.000882	CcSEcCtD
Bexarotene—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.000882	CcSEcCtD
Bexarotene—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.000882	CcSEcCtD
Bexarotene—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.000881	CcSEcCtD
Bexarotene—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000297	0.000879	CcSEcCtD
Bexarotene—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000296	0.000875	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000295	0.000872	CcSEcCtD
Bexarotene—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000294	0.000871	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—TNF—chronic obstructive pulmonary disease	0.000294	0.00275	CbGpPWpGaD
Bexarotene—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.000868	CcSEcCtD
Bexarotene—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000293	0.000866	CcSEcCtD
Bexarotene—Pain—Montelukast—chronic obstructive pulmonary disease	0.000292	0.000864	CcSEcCtD
Bexarotene—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000291	0.000862	CcSEcCtD
Bexarotene—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.00029	0.000859	CcSEcCtD
Bexarotene—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.000857	CcSEcCtD
Bexarotene—Purpura—Prednisone—chronic obstructive pulmonary disease	0.00029	0.000857	CcSEcCtD
Bexarotene—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000289	0.000855	CcSEcCtD
Bexarotene—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000289	0.000854	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000288	0.00269	CbGpPWpGaD
Bexarotene—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000288	0.000851	CcSEcCtD
Bexarotene—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.00085	CcSEcCtD
Bexarotene—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000287	0.00085	CcSEcCtD
Bexarotene—RXRA—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000287	0.00268	CbGpPWpGaD
Bexarotene—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000287	0.000849	CcSEcCtD
Bexarotene—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.000847	CcSEcCtD
Bexarotene—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000286	0.000845	CcSEcCtD
Bexarotene—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000285	0.000843	CcSEcCtD
Bexarotene—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.000843	CcSEcCtD
Bexarotene—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000285	0.000843	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000284	0.000841	CcSEcCtD
Bexarotene—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000284	0.00084	CcSEcCtD
Bexarotene—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.000833	CcSEcCtD
Bexarotene—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.000833	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000279	0.00261	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000279	0.000826	CcSEcCtD
Bexarotene—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000279	0.000826	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000278	0.00259	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000277	0.00259	CbGpPWpGaD
Bexarotene—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.000815	CcSEcCtD
Bexarotene—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.000815	CcSEcCtD
Bexarotene—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000276	0.000815	CcSEcCtD
Bexarotene—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000276	0.000815	CcSEcCtD
Bexarotene—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000275	0.000813	CcSEcCtD
Bexarotene—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000275	0.000813	CcSEcCtD
Bexarotene—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000272	0.000806	CcSEcCtD
Bexarotene—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000272	0.000805	CcSEcCtD
Bexarotene—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000272	0.000805	CcSEcCtD
Bexarotene—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.000803	CcSEcCtD
Bexarotene—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000271	0.000801	CcSEcCtD
Bexarotene—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00027	0.000799	CcSEcCtD
Bexarotene—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00027	0.000799	CcSEcCtD
Bexarotene—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.00027	0.000797	CcSEcCtD
Bexarotene—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.000796	CcSEcCtD
Bexarotene—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000267	0.00079	CcSEcCtD
Bexarotene—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000266	0.000786	CcSEcCtD
Bexarotene—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000265	0.000782	CcSEcCtD
Bexarotene—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00077	CcSEcCtD
Bexarotene—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00077	CcSEcCtD
Bexarotene—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00076	CcSEcCtD
Bexarotene—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00076	CcSEcCtD
Bexarotene—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000257	0.000759	CcSEcCtD
Bexarotene—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000256	0.000757	CcSEcCtD
Bexarotene—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000254	0.000752	CcSEcCtD
Bexarotene—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000252	0.000744	CcSEcCtD
Bexarotene—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00074	CcSEcCtD
Bexarotene—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00074	CcSEcCtD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000249	0.00233	CbGpPWpGaD
Bexarotene—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00073	CcSEcCtD
Bexarotene—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00073	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000246	0.000728	CcSEcCtD
Bexarotene—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000246	0.000728	CcSEcCtD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000246	0.00229	CbGpPWpGaD
Bexarotene—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000245	0.000725	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000245	0.00229	CbGpPWpGaD
Bexarotene—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000243	0.000719	CcSEcCtD
Bexarotene—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.000718	CcSEcCtD
Bexarotene—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000242	0.000715	CcSEcCtD
Bexarotene—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000239	0.000706	CcSEcCtD
Bexarotene—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.000706	CcSEcCtD
Bexarotene—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000237	0.000702	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—IL6—chronic obstructive pulmonary disease	0.000237	0.00222	CbGpPWpGaD
Bexarotene—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000237	0.0007	CcSEcCtD
Bexarotene—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.000699	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—chronic obstructive pulmonary disease	0.000235	0.00219	CbGpPWpGaD
Bexarotene—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000234	0.000691	CcSEcCtD
Bexarotene—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.000689	CcSEcCtD
Bexarotene—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.000684	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000231	0.00216	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—APIP—chronic obstructive pulmonary disease	0.000231	0.00216	CbGpPWpGaD
Bexarotene—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000231	0.000682	CcSEcCtD
Bexarotene—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.000682	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000226	0.00211	CbGpPWpGaD
Bexarotene—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000226	0.000668	CcSEcCtD
Bexarotene—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000668	CcSEcCtD
Bexarotene—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.000666	CcSEcCtD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000223	0.00208	CbGpPWpGaD
Bexarotene—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000222	0.000657	CcSEcCtD
Bexarotene—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000222	0.000656	CcSEcCtD
Bexarotene—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.000656	CcSEcCtD
Bexarotene—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00065	CcSEcCtD
Bexarotene—Rash—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00065	CcSEcCtD
Bexarotene—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00065	CcSEcCtD
Bexarotene—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00065	CcSEcCtD
Bexarotene—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00022	0.00065	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—chronic obstructive pulmonary disease	0.000219	0.00205	CbGpPWpGaD
Bexarotene—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.000646	CcSEcCtD
Bexarotene—Headache—Formoterol—chronic obstructive pulmonary disease	0.000218	0.000646	CcSEcCtD
Bexarotene—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000646	CcSEcCtD
Bexarotene—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.000644	CcSEcCtD
Bexarotene—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000644	CcSEcCtD
Bexarotene—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000217	0.000642	CcSEcCtD
Bexarotene—Rash—Montelukast—chronic obstructive pulmonary disease	0.000215	0.000637	CcSEcCtD
Bexarotene—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000215	0.000636	CcSEcCtD
Bexarotene—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000215	0.000635	CcSEcCtD
Bexarotene—Headache—Montelukast—chronic obstructive pulmonary disease	0.000214	0.000633	CcSEcCtD
Bexarotene—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000211	0.000624	CcSEcCtD
Bexarotene—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.000619	CcSEcCtD
Bexarotene—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.000617	CcSEcCtD
Bexarotene—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.000615	CcSEcCtD
Bexarotene—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.000614	CcSEcCtD
Bexarotene—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.000614	CcSEcCtD
Bexarotene—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.000614	CcSEcCtD
Bexarotene—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000207	0.000613	CcSEcCtD
Bexarotene—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.000613	CcSEcCtD
Bexarotene—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00061	CcSEcCtD
Bexarotene—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000203	0.000602	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000203	0.0019	CbGpPWpGaD
Bexarotene—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000203	0.0006	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000202	0.00189	CbGpPWpGaD
Bexarotene—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.000591	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000196	0.00183	CbGpPWpGaD
Bexarotene—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.000579	CcSEcCtD
Bexarotene—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.000576	CcSEcCtD
Bexarotene—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000574	CcSEcCtD
Bexarotene—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000193	0.000571	CcSEcCtD
Bexarotene—RXRG—Gene Expression—CTGF—chronic obstructive pulmonary disease	0.000192	0.0018	CbGpPWpGaD
Bexarotene—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000561	CcSEcCtD
Bexarotene—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000189	0.000559	CcSEcCtD
Bexarotene—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.00055	CcSEcCtD
Bexarotene—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.000545	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000183	0.00171	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000183	0.00054	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	0.000182	0.0017	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—CTGF—chronic obstructive pulmonary disease	0.000181	0.00169	CbGpPWpGaD
Bexarotene—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000534	CcSEcCtD
Bexarotene—RXRG—Gene Expression—HDAC2—chronic obstructive pulmonary disease	0.000179	0.00168	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000177	0.00166	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000175	0.00164	CbGpPWpGaD
Bexarotene—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000175	0.000518	CcSEcCtD
Bexarotene—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00051	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000172	0.00161	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	0.000171	0.0016	CbGpPWpGaD
Bexarotene—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.000505	CcSEcCtD
Bexarotene—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000505	CcSEcCtD
Bexarotene—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.00017	0.000502	CcSEcCtD
Bexarotene—RXRB—Gene Expression—HDAC2—chronic obstructive pulmonary disease	0.000169	0.00158	CbGpPWpGaD
Bexarotene—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000497	CcSEcCtD
Bexarotene—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000497	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000165	0.00154	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000164	0.00153	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000162	0.00151	CbGpPWpGaD
Bexarotene—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000161	0.000478	CcSEcCtD
Bexarotene—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000461	CcSEcCtD
Bexarotene—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00046	CcSEcCtD
Bexarotene—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000155	0.00046	CcSEcCtD
Bexarotene—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000457	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	0.000154	0.00144	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000153	0.00143	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000152	0.00142	CbGpPWpGaD
Bexarotene—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000449	CcSEcCtD
Bexarotene—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000447	CcSEcCtD
Bexarotene—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000446	CcSEcCtD
Bexarotene—RXRA—Metabolism—GC—chronic obstructive pulmonary disease	0.000149	0.00139	CbGpPWpGaD
Bexarotene—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000437	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000148	0.00138	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00136	CbGpPWpGaD
Bexarotene—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000429	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—TNF—chronic obstructive pulmonary disease	0.000144	0.00135	CbGpPWpGaD
Bexarotene—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000423	CcSEcCtD
Bexarotene—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000423	CcSEcCtD
Bexarotene—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000422	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000421	CcSEcCtD
Bexarotene—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000141	0.000418	CcSEcCtD
Bexarotene—RXRA—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000141	0.00131	CbGpPWpGaD
Bexarotene—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.000412	CcSEcCtD
Bexarotene—RXRA—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000138	0.00129	CbGpPWpGaD
Bexarotene—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000406	CcSEcCtD
Bexarotene—Infection—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000403	CcSEcCtD
Bexarotene—Shock—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000399	CcSEcCtD
Bexarotene—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000398	CcSEcCtD
Bexarotene—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000396	CcSEcCtD
Bexarotene—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000394	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000133	0.00124	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000392	CcSEcCtD
Bexarotene—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000387	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000125	0.00037	CcSEcCtD
Bexarotene—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000369	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000125	0.00117	CbGpPWpGaD
Bexarotene—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000367	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000124	0.00116	CbGpPWpGaD
Bexarotene—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000365	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000123	0.00115	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000121	0.00113	CbGpPWpGaD
Bexarotene—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000357	CcSEcCtD
Bexarotene—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000353	CcSEcCtD
Bexarotene—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000352	CcSEcCtD
Bexarotene—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000352	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000119	0.00111	CbGpPWpGaD
Bexarotene—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00035	CcSEcCtD
Bexarotene—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00035	CcSEcCtD
Bexarotene—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000347	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000117	0.00109	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IL6—chronic obstructive pulmonary disease	0.000116	0.00109	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000116	0.00108	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000114	0.00106	CbGpPWpGaD
Bexarotene—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000335	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000113	0.00106	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000332	CcSEcCtD
Bexarotene—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.000332	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000112	0.00104	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000111	0.00104	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00103	CbGpPWpGaD
Bexarotene—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000321	CcSEcCtD
Bexarotene—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000321	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.001	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000107	0.001	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	0.000106	0.00099	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000106	0.000988	CbGpPWpGaD
Bexarotene—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000299	CcSEcCtD
Bexarotene—Asthenia—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000291	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.73e-05	0.000909	CbGpPWpGaD
Bexarotene—Pruritus—Prednisone—chronic obstructive pulmonary disease	9.71e-05	0.000287	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.59e-05	0.000896	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—CTGF—chronic obstructive pulmonary disease	9.43e-05	0.000881	CbGpPWpGaD
Bexarotene—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	9.39e-05	0.000278	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.34e-05	0.000873	CbGpPWpGaD
Bexarotene—Dizziness—Prednisone—chronic obstructive pulmonary disease	9.07e-05	0.000268	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	8.93e-05	0.000834	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—HDAC2—chronic obstructive pulmonary disease	8.79e-05	0.000821	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	8.78e-05	0.00082	CbGpPWpGaD
Bexarotene—Vomiting—Prednisone—chronic obstructive pulmonary disease	8.73e-05	0.000258	CcSEcCtD
Bexarotene—Rash—Prednisone—chronic obstructive pulmonary disease	8.65e-05	0.000256	CcSEcCtD
Bexarotene—Dermatitis—Prednisone—chronic obstructive pulmonary disease	8.64e-05	0.000256	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	8.62e-05	0.000806	CbGpPWpGaD
Bexarotene—Headache—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000254	CcSEcCtD
Bexarotene—RXRB—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	8.25e-05	0.000771	CbGpPWpGaD
Bexarotene—Nausea—Prednisone—chronic obstructive pulmonary disease	8.15e-05	0.000241	CcSEcCtD
Bexarotene—RXRA—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.13e-05	0.00076	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	8.11e-05	0.000758	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GCLC—chronic obstructive pulmonary disease	8.04e-05	0.000751	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8e-05	0.000748	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.49e-05	0.0007	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.46e-05	0.000697	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.35e-05	0.000687	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CTGF—chronic obstructive pulmonary disease	7.33e-05	0.000685	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.13e-05	0.000666	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.07e-05	0.00066	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.97e-05	0.000651	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.76e-05	0.000631	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP9—chronic obstructive pulmonary disease	6.44e-05	0.000602	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	6.15e-05	0.000574	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	5.78e-05	0.00054	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.71e-05	0.000534	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	5.69e-05	0.000531	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.66e-05	0.000529	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.64e-05	0.000527	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.56e-05	0.000519	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	5.56e-05	0.000519	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	5.31e-05	0.000496	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—chronic obstructive pulmonary disease	5.2e-05	0.000486	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.18e-05	0.000484	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.17e-05	0.000483	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—chronic obstructive pulmonary disease	4.96e-05	0.000463	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.91e-05	0.000459	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	4.3e-05	0.000402	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.12e-05	0.000385	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6—chronic obstructive pulmonary disease	4e-05	0.000374	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.77e-05	0.000352	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	3.66e-05	0.000342	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.41e-05	0.000318	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALB—chronic obstructive pulmonary disease	3.34e-05	0.000312	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NOS3—chronic obstructive pulmonary disease	3.19e-05	0.000298	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.04e-05	0.000284	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	3e-05	0.00028	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.8e-05	0.000261	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	2.74e-05	0.000256	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.52e-05	0.000236	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.1e-05	0.000197	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.07e-05	0.000194	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2e-05	0.000187	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.98e-05	0.000185	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.93e-05	0.000181	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.83e-05	0.000171	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.81e-05	0.000169	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.66e-05	0.000155	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.39e-05	0.00013	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.37e-05	0.000128	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.28e-05	0.000119	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	1.25e-05	0.000116	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.21e-05	0.000113	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	1.19e-05	0.000111	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	8.22e-06	7.68e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	7.86e-06	7.34e-05	CbGpPWpGaD
